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Summary
Background Pompe disease is an inheritable metabolic disor-
der for which enzyme replacement therapy (ERT) has been
available since 2006. Effects of ERT have been shown on
distance walked, pulmonary function and survival. We inves-
tigated whether it also improves quality of life and participa-
tion in daily life in adult patients with the disease.
Methods In an international survey, we assessed quality of life
(Short Form 36, SF-36) and participation (Rotterdam Handi-
cap Scale, RHS) annually between 2002 and 2012. Repeated
measurements mixed effects models were used to describe the
data over time.
Results Responses were available for 174 adult patients. In
the periods before and after start of ERT, the median
follow-up times were 4 years each (range 0.5-8). The SF-
36 Physical Component Summary measure (PCS) deterio-
rated before ERT (-0.73 score points per year (sp/y); CI
95 % -1.07 to -0.39), while it improved in the first 2 years
of ERT (1.49 sp/y; CI 0.76 to 2.21), and remained stable
thereafter. The Mental Component Summary measure
(MCS) remained stable before and during ERT. After de-
clining beforehand (-0.49 sp/year; CI -0.64 to-0.34), the
RHS stabilized under ERT.
Conclusion In adult patients with Pompe disease, ERT pos-
itively affects quality of life and participation in daily life.
Our results reinforce previous findings regarding the effect
of ERT on muscle strength, pulmonary function and
survival.
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Introduction
Pompe disease (OMIM 232300) is an inheritable metabol-
ic disorder caused by a deficiency of the lysosomal en-
zyme acid α-glucosidase, which is needed to break down
glycogen (Hirschhorn and Reuser 2001). Lysosomal gly-
cogen consequently accumulates in cells throughout the
body, particularly in muscle cells, resulting in a wide
spectrum of symptoms and complications (Gungor and
Reuser 2013). Typically, adult patients have skeletal and/
or respiratory muscle weakness, as well as symptoms such
as pain (Gungor et al 2013) and fatigue (Gungor et al
2013; Hagemans et al 2007b). Most eventually become
wheelchair-bound or require respiratory support. They
are at risk of succumbing to respiratory failure or insuffi-
ciency. The resulting impact of the disease on their quality
of life (QoL) and their participation in daily life is sub-
stantial. Many patients are limited in their ability to work
or study (Hagemans et al 2007a), and their physical health
status has been shown to be less than that of people in the
general population (Hagemans et al 2004; van der Ploeg
et al 2010; Vielhaber et al 2011). On the other hand, their
mental-health status was found not be reduced (Hagemans
et al 2004; Kanters et al 2011; Wokke et al 2008).
Cur ren t ly, enzyme rep lacement therapy wi th
alglucosidase alfa is the only approved treatment for
Pompe disease. By improving and stabilizing skeletal mus-
cle strength and function, and respiratory function, this
lifelong treatment has improved the prospects of adult pa-
tients with the disease (Gungor et al 2013; Toscano and
Schoser 2013; van der Ploeg et al 2010). Most importantly,
ERT improves survival (Gungor et al 2013). However, it is
less clear whether it also improves patients’ quality of life
and participation, especially after longer treatment. The
only placebo-controlled clinical trial to have assessed the
efficacy of ERT in 90 adult patients showed that physical
health status (measured by the SF-36) after 18 months of
ERT did not differ between the placebo group and the
treatment group (van der Ploeg et al 2010). And while
the only observational study to include quality of life
(measured using the SF-36) in its assessment of the effects
of ERT indicated that QoL remained stable during treat-
ment (Regnery et al 2012; Strothotte et al 2010), several
individual case reports and case series reported improve-
ments (Merk et al 2009; Orlikowski et al 2011; Vielhaber
et al 2011; Angelini et al 2009).
To the best of our knowledge, no study in large groups
of patients has determined whether ERT affects longer-
term Qol. Neither has the effect of ERT on participation
been studied. To fill these gaps in knowledge, we studied
the QoL and participation in daily life of adults with
Pompe diseases before and after long-term treatment with
ERT.
Methods
Data collection
This study was performed as part of an ongoing prospective
observational cohort study in patients with Pompe disease that
started in May 2002. Information was collected through an-
nual surveys sent out by mail and, since May 2009, also col-
lected through a secure web-interphase. Questionnaires cov-
ered data on medical history, patient demographics, quality of
life and participation in daily life (Hagemans et al 2005a, b).
Patients from the Netherlands, the United States, the United
Kingdom, Germany and Australia were recruited through the
national patient organizations, as were a smaller number of
patients from other countries. In addition, Dutch patients were
also recruited through the Erasmus MC University Center for
Lysosomal and Metabolic Diseases, the national referral cen-
ter for Pompe disease. Data collection for the current study
was locked in February 2012; it included only adult patients
aged 18 years and older who had started treatment at some
point during follow-up. To be included in the analyses, pa-
tients had to have been receiving ERT for at least 6 months,
and also to have had a minimum of 6 months follow-up before
the start of ERT. The study was approved by the ethics com-
mittee of the Erasmus MC University Medical Center and
written informed consent was obtained from all participants
Measurement scales
Quality of life
Quality of life was measured using the Medical Outcome
Study 36-item Short Form Health Survey (SF-36), a generic
instrument that has been widely used, has been translated into
many languages, and has been shown to have good reliability
and validity (McHorney et al 1993; Wagner et al 1998; Ware
and Sherbourne 1992). It comprises eight domains: physical
functioning, role physical, bodily pain, general health, vitality,
social functioning, role emotional and mental health. Items are
summed per domain and transformed into scores between 0-
100, with higher values representing better function. Two
summary scores can also be derived from the SF-36: the phys-
ical component summary measure (PCS) and the mental com-
ponent summary measure (MCS). Norm-based scores were
calculated using the US 1998 norm-based scoring for all pa-
tients; this is common practice, as the differences with
country-based norm-scores have been shown to be very small
for data collected in Western European countries (Ware et al
1998). Norm-based scoring assures that results for both ver-
sions of the SF-36 can be directly compared. In our study, we
used SF36 version 1.0 between 2002 and 2009, and version 2
in the years thereafter.
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Participation in daily life activities
To assess the level of Participation, which is defined as a
person’s involvement in life situations (previously called
‘Handicap’) (WHO 1980, 2001), we used the Rotterdam
Handicap Scale (RHS). The RHS is a brief measurement scale
consisting of nine items covering mobility, domestic tasks and
leisure activities (each assessed indoors and outdoors), as well
as kitchen tasks, driving a car/going by bus/ride a bicycle and
work/study. The scores per item range from 1 (‘unable to fulfil
the task or activity’) to 4 (‘complete fulfilment of the task or
activity’). Patients can also answer that an item does not apply
to them, in which case a score of 0 is given. The total score is
calculated as the sum of the item scores divided by the number
of applicable items and multiplied by 9 (Hagemans et al
2007a; Merkies et al 2002). The RHS score thus ranges from
9 to 36. In the present analysis, no score was calculated if 4 or
more items were non-applicable or missing. As a result, 2 % of
measurements (32/1358) were excluded from analyses.
Statistical analyses
The longitudinally assessed outcome scores (PCS andMCS of
the SF-36; RHS) were analysed using mixed effects models,
which allowed for irregular measurement times and different
treatment/follow-up durations, including the fact that not all
patients had measurements that dated from exactly the start of
ERT. In the fixed-effects part, piece-wise linear regression was
used to assess the mean annual change in the outcome scores
in different time periods; the scores were expressed in absolute
score points (sp/y). Whenever it was possible to assume line-
arity in the changes in outcome scores within the periods be-
fore and after the start of ERT, we used the ‘broken-stick
method’, in which the breakpoint was chosen at the time that
ERT was started. Linearity was statistically assessed on the
basis of inclusion of a quadratic term for time (p<0.05) and
also by inspecting the Loess nonparametric smoother. If the
changes in outcome scores before or after ERTwere not linear,
this non-linear time period was divided into two smaller linear
segments, in which further breakpoints were placed at
2.0 years of ERT, based on our clinical knowledge and the
Loess nonparametric smoother.
Subgroup analyses were performed to assess whether a
treatment effect, if any, differed between more and less severe-
ly affected patients. Disease severity was defined as wheel-
chair use (yes/no) and use of respiratory support (yes/no).
Using the likelihood ratio test we first assessed whether
adding a subgroup significantly improved the mixed effects
model (p<0.05). If so, the variable, and its interactions with
time were included in the model and interpreted.
Data analyses used SPSS for Windows (version 17, SPSS
Inc., Chicago, IL) and SAS (version 9.2, SAS Institute Inc.,
Cary, NC). A p-value of≤0.05 was considered statistically
significant.
Results
Patients
One hundred and seventy-four adult Pompe patients were
available for the current analysis. Figure 1 shows the inclusion
process. There were three reasons for excluding adult patients:
not receiving ERT (n=59), no follow-up measurements avail-
able (n=99) and less than six months follow-up either before
or after the start of ERT (n=38). At baseline, excluded patients
were comparable to those included in the analysis in terms of
gender and disease severity, but not with regard to age. Ex-
cluded patients were slightly older (median 51 years, (range
20-81 years) vs 46 years (range 19-72 years; p=0.001)).
Table 1 shows the characteristics of the study population.
Fifty-three percent of the participants were women. Patients’
median age at start of ERTwas 50 years (range 24-76); 52 %
used a wheelchair, and 48 % required respiratory support. The
median total follow-up time was 7 years (range 1-10), with a
median follow-up period of 4 years (range 0.5-8) both before
and during ERT.
At start of ERT, patients had a median PCS score of 31,
well below the general population norm of 50, while their
Participants in Pompe 
Survey/Erasmus MC
(n=399)
Participants  18 years
(n=370)
Participants with <6 
month s before the s tart of 
or  during ERT (n=38)
Participants who had 
never received ERT
(n=59)
No follow-up 
measurements (n=99) 
Study pop ulation for 
analyses (n=174)
Participants <18 years
(n= 29)
Fig. 1 Flowchart of the study population for the analyses
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median MCS score of 54 was within the normal range. Pa-
tients’ had a median RHS score of 25 at the start of ERT,
which was below the maximum score of 36 that would be
scored by an average healthy person.
Effect of ERT on quality of life
During ERT, PCS and MCS scores did not follow a linear
pattern over time. We therefore distinguished two time inter-
vals during ERT: 1. from start of ERT to two years of ERT, 2.
and more than two years of ERT (see Table 2).
In the period before starting ERT, the PCS decreased sig-
nificantly by 0.73 score points per year (sp/y; CI 95% -1.07 to
-0.39). This was followed in the first two years after treatment
by a significant increase of 1.49 sp/y (CI 95 % 0.76 to 2.21),
and by stabilization thereafter (-0.15 sp/y; CI 95 % -0.43 to
0.13). The MCS was more or less stable during the entire
follow-up period.
Table 2 also shows the separate changes in the eight health
domains of the SF36. Throughout treatment follow-up, the
physical functioning, role physical, general health and vitality
domains increased, with particularly large increases during the
first two years of ERT in role physical (9 sp/y), general health
(5 sp/y) and vitality (4 sp/y). Mental-health domain scores
increased until 2 years of ERT (2 sp/y), while bodily pain,
social functioning and role emotional did not increase during
Table 1 Characteristics of the study population
Demographics Study population
N=174
Age at start of ERT, median (range) 50 (24–76)
Age at diagnosis, median (range) 37 (1–66)
Female gender, no. (%) 93 (53)
Country of residence, no. (%)
Netherlands 64 (37)
Germany 36 (21)
US 39 (22)
UK 16 (9)
Other 19 (11)
Clinical characteristics
Disease duration, median (range) 12 (1–33)
Use of wheelchair at start of ERT, no. (%) 90 (52)
Respiratory support at start of ERT, no. (%)* 84 (48)
Follow-up during study
Total follow-up time, median (range) 7 (1–10)
Pre-treatment period, median (range) 4 (0.5–8)
Treatment period, median (range) 4 (0.5–8)
Age, disease duration and follow-up time are expressed in years as me-
dian (range). Categorical variables are expressed as number (no.) and
percentage (%);
*FRespiratory support’ includes partial and fulltime, invasive and non-
invasive respiratory support
Table 2 SF-36 quality of life scores before and during ERT
Clinical outcome measure Follow-up time intervals (in years)
SF-36 Component summary scores Pre-ERT
Mean sp/y (95 % CI)
0 to 2 years during ERT
Mean sp/y (95 % CI)
>2 years during ERT
Mean sp/y (95 % CI)
Physical component summary -0.73 (-1.07; -0.39)** 1.49 (0.76; 2.21)** -0.15 (-0.43; 0.13)
Mental component summary 0.16 (-0.25; 0.57) 1.03 (-0.07; 2.13) 0.02 (-0.41; 0.46)
SF-36 domain scores
Physical functioning -1.80 (-2.41; -1.19)** 1.81 (0.38; 3.23)* 0.68 (0.12; 1.25)*
Role physical -1.20 (-2.92; 0.52) 9.18 (5.83; 12.53)** 2.46 (1.15; 3.77)**
Bodily pain -2.10 (-3.01; -1.19) ** 0.76 (-1.39; 2.92) -1.96 (-2.95; -0.98)**
General health 0.19 (-0.49; 0.87) 5.22 (3.58; 6.86)** 0.81 (0.13; 1.49)*
Vitality -0.44 (-1.11; 0.24) 4.10 (2.44; 5.76)** 1.43 (0.77; 2.09)**
Social functioning -0.74 (-1.66; 0.18) 2.11 (-0.16; 4.39) 0.41 (-0.54; 1.35)
Role emotional -0.15 (-1.64; 1.34) 3.05 (-1.06; 7.16) 0.19 (-1.15; 1.53)
Mental health 0.13 (-0.60; 0.87) 2.09 (0.57; 3.61)** 0.29 (-0.37; 0.95)
Rotterdam handicap scale score Pre-ERT
Mean sp/y (95 % CI)
During ERT
Mean sp/y (95 % CI)
-0.49 (-0.64;-0.34)** -0.02 (-0.17; 0.13)
Data shown are mean changes in score points per year (sp/y) as calculated by univariate analysis using mixed model ANOVA
CI confidence interval
*Change is significant at the 0.05 level, **Change is significant at the 0.01 level
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treatment. In fact, bodily pain seemed to deteriorate in the later
years of ERT, as it had before starting ERT.
Using the results from the statistical analysis presented
above we calculated the expected SF-36 scores at three time-
points: 4 years before ERT, at start of ERTand after 4 years of
ERT (Fig. 2). Before starting treatment, the PCS and the do-
mains physical functioning, role physical and vitality were
below the general population norm. While all four improved
with treatment, the PCS and the physical functioning domain
scores remained below the population norm after 4 years of
ERT.
Subgroup analyses showed that less severely affected pa-
tients (i.e. those not using a wheelchair or not using a ventila-
tor) overall had better PCS scores than more severely affected
patients (p<0.01). MCS scores did not differ between these
two groups. Subgroup analyses did not show any differences
in the effect of ERT on the PCS or MCS scores between more
and less severely affected patients.
Effect of ERT on participation in daily life
Because with regard to the RHS the changes in the periods
before and after the start of ERTcould be assumed to be linear,
the breakpoint was set only at the start of ERT. Before starting
ERT, RHS scores decreased significantly by a mean of 0.49
sp/y (CI 95 % -0.63 to -0.34). During ERT, however, they
stabilized (-0.02 sp/y; CI 95 % -0.17 to 0.13; Table 2). Sub-
group analyses showed that less severely affected patients had
better RHS scores overall, but it did not show any differences
in the effect of ERT on participation between more and less
severely affected patients.
Discussion
This study in a large international cohort of patients with
Pompe disease showed enzyme replacement therapy to have
a positive effect on patients’ physical health status (PCS) and
their participation in daily life. The use of ERT halted the
progressive decline in physical health status and participation
observed pre-treatment; during the first two years of ERT
patients’ physical health status even improved. Patients’
mental-health status (MCS) remained the same throughout
the entire follow-up including the pre-treatment period.
The significant improvement in the PCS during the first
two years of treatment was most noticeable in the role physical
domain, which increased by 9 score-points per year, reflecting
a large increase in patients’ ability to perform their work and
other common activities. Two physical health domains were
below the population norm in our Pompe cohort: physical
functioning and role physical (see also Hagemans et al
2004). These domains improved over the entire treatment fol-
low-up, as did general health, explaining the increase in PCS
scores after the start of ERT.
The improvements in the physical functioning and role
physical domains may have been due to the positive effect of
ERT on muscle function and strength seen in other studies
(Angelini et al 2012; Bembi et al 2010; de Vries et al 2012;
Orlikowski et al 2011; Regnery et al 2012; van der Ploeg et al
2012; van der Ploeg et al 2010). In addition to the three do-
mains that improved, bodily pain is important to determining
the PCS level. In the first two years after the start of ERT, bodily
pain stabilized, but with longer treatment it declined, indicating
more pain. This may signify that ERT is only partially curative.
Only one other study (in two patients) has provided information
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on the effect of ERTon pain; this showed that pain decreased in
the year after the start of ERT (Vielhaber et al 2011). Recently,
pain was also shown to be a relatively common symptom in
treated and untreated patients alike (Gungor et al 2013).
Ours is the first study in adult Pompe patients to examine
the effect of ERT on their participation in daily life. Patients’
reduced physical health status at start of ERTwas mirrored by
their lower level of participation in daily life. The impact of
Pompe disease on participation and the decline in participation
over time before ERT has previously been described in a
group of 40 Dutch patients (Hagemans et al 2006), and was
confirmed by the current study. Compared to the decline ob-
served prior to ERT, the stabilization that took place during
treatment should be seen as an important effect of therapy: for
patients with Pompe disease, it is very valuable to maintain
rather than lose a certain level of social activities.
Our observation that the MCS remained stable even with-
out treatment is consistent with the outcomes of previous stud-
ies showing that adult Pompe patients have the same mental-
health status as healthy individuals (Hagemans et al 2004;
Kanters et al 2011). Over time, patients with a chronic disease
such as Pompe disease may adapt to their situation by chang-
ing their standards, values and conceptualizations; this may
explain their stable mental-health scores during follow-up.
During ERT, there was an improvement in only one of the
four domains that chiefly determine the MCS: vitality, which
assesses the level of energy. This corroborates previous find-
ings in this cohort in which ERT reduced the level of fatigue
measured by the Fatigue Severity Scale (Gungor et al 2013).
As shown in earlier analyses of this survey, more severely
affected patients had worse physical health and handicap
scores than those less severely affected (Hagemans et al
2004 and Hagemans et al 2007a). Nevertheless, no difference
was observed between these groups in the effect of ERT on
these outcome measures. While this could suggest that ERT is
equally beneficial in the experience of the patient, the results
of these subgroup analyses should be interpreted with caution
as we could not adjust for other factors that may differ be-
tween these patients.
This is the first time that significant positive effects of ERT
on physical health status (PCS) have been demonstrated in
such a large study with long follow-up, although they have
been suggested by some other studies (Orlikowski et al 2011;
Toscano and Schoser 2013). There are two possible reasons
why such positive effects were not demonstrated by the piv-
otal 18-month placebo-controlled trial by van der Ploeg et al
on the effects of ERT (van der Ploeg et al 2010). Firstly, while
the original trial had a smaller study population, with 60 pa-
tients in the treatment arm and 30 in the placebo arm, our own
study followed 174 patients both before and after the start of
therapy. Secondly, while follow-up in the original trial was
78 weeks, median follow-up in our study was 4 years before
start of ERT and 4 years afterwards. The fact that sufficient
follow-up time and a large number of patients are requiredwas
also demonstrated by our earlier study of 38 untreated Dutch
patients, a limited study with only one year of follow-up in
which we found no significant deterioration in physical health
status (Hagemans et al 2004). The same population was in-
cluded in the current study: now, with a long pre-treatment
period and a larger study group, the deterioration in PCS in
untreated patients became significant.
Randomized controlled trials are generally seen as the gold
standard for assessing the effects of treatment. However, while
they are an important means of showing the short-term effect
of drugs, their limited duration does not allow for the assess-
ment of long-term treatment effects. Our own longitudinal
survey supplements the evidence obtained from such trials
by enabling the long-term treatment effects to be evaluated
in a broad patient population that also includes severely af-
fected patients who would normally be excluded from a trial.
It is also the case that international surveys and registries are
the only way to obtain sufficient patient numbers for rare
disorders such as Pompe disease. Our study thus has the ad-
vantage of incorporating a large cohort of Pompe patients of
different ages and severities across different countries over a
long follow-up period (up to 10 years).
The recruitment of patients through patient organizations
might be seen as a limitation of this study, as it could result in
the exclusion of patients at the more or less severe end of the
spectrum. However, the demographic and clinical characteris-
tics of our study population show that patients were included
across the entire spectrum of adult Pompe disease. Although
the SF-36 is a generic instrument that may not necessarily
cover all the domains that are relevant in Pompe disease, we
chose to use it because it is readily available and is also widely
used in many different disorders. While more comprehensive
information could be derived by using a disease-specific scale
such as the R-Pact (van der Beek et al 2013), the R-Pact was
not available when the survey was started.
Because patients’ perceptions of their health-related quality
of life and participation in daily life can provide important
information about the impact of a disease on patients’ lives,
they are increasingly used in clinical research and practice. In
2006, the Food and Drug Administration (FDA) and The Eu-
ropean Agency for the Evaluation of Medicinal Products
(EMEA) both acknowledged the importance of such out-
comes (US. FDA 2009; European Medicine Agency 2004).
In the study of Pompe disease, the chronic progressive char-
acter of the disease means that patients will probably need
lifelong therapy. While patients’ lives might be negatively
affected by the possible burden of bi-weekly infusions, our
results show that this burden is outweighed by the positive
effects of ERT.
In conclusion ERT positively affects quality of life and
participation in daily life of adult Pompe patients. Before treat-
ment, physical health status and participation declined
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progressively. After the start of ERT, both stabilized. The ef-
fect on physical health status seemed to be greatest in the first
two years after ERT. The mental-health status of these patients
did not seem to be affected. These results reinforce the evi-
dence available on the efficacy of ERT, showing that as well as
its beneficial effect on muscle strength, pulmonary function
and survival, ERT also improves patients’ perceived partici-
pation and quality of life.
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